Amylyx says Phase 3 LUCIDITY trial of avexitide cuts post-bariatric hypoglycemia events 55% vs placebo

• Amylyx reported positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia following Roux-en-Y surgery.
• The trial showed fewer serious hypoglycemic events versus placebo, supporting a potential first approved therapy for the condition.
• Management plans to file a New Drug Application with the FDA by end of 2026, targeting a 2027 launch if cleared.
• Data will be presented at a future medical meeting; an open-label extension remains ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260817275387) on August 18, 2026, and is solely responsible for the information contained therein.